From Start-Up to Scale-Up


BeyondBio SCALE is a 9-month program dedicated to helping startups navigate the challenging journey from start-up to scale-up. An interdisciplinary team from AstraZeneca and our global partners - Accenture, AWS, Clalit Health Services will share world-class insights, expertise, resources, connections and guidance equipping your startup with the tools and business links to accelerate deployment at scale.

BeyondBio SCALE program is part of AstraZeneca’s BeyondBio Innovation Hub activity in Israel and the A.Catalyst global Innovation hub network by AstraZeneca. At BeyondBio our vision is to improve healthcare by advancing cutting-edge science, technology, and innovation from Israel and reaching patients and healthcare systems around the globe. 


You have built a great startup. BeyondBio SCALE can help you grow successfully and efficiently.

To ensure mutual compatibility, we will first assess your solution and its ability to address key challenges in the following clinical focus areas:

  • Respiratory and Immunology
  • Cardiovascular, Renal & Metabolic Diseases 
  • Oncology
  • Vaccines and Infections

The most relevant and promising solutions will be accepted to the BeyondBio SCALE program. Every participating company will receive support tailored to its unique needs. 


Welcome to the BeyondBio SCALE program!

Together with our program partners – AstraZeneca, Accenture, AWS and Clalit Health Services, we will identify a scalable use case for your solution.

We will engage “champions” from our global organizations and will introduce you to relevant experts, resources and senior business leaders who can help propel your solution onto the global stage.


Based on the use case, your solution will be analyzed from different angles including commercial, clinical, regulatory, technology and business perspectives. We will stress-test, revise and iterate together, utilizing core competencies of the program partners as needed. 

We will jointly set a series of practical discussions with relevant stakeholders, aspiring to achieve maximum readiness for growth.

The goal of this process is the creation of a detailed plan for scaling.


Now you are ready to deploy your solution, implementing the right model and metrics for your use case. A pilot abroad, a validation study, a collaboration agreement, or a product launch at scale can all be considered.

This process doesn’t end after the 9-month program. The foundations and connections we build together will continue to evolve beyond the program duration.

Ultimately, the goal is for your solution to reach scale – successfully and efficiently.

Ready to SCALE? 




We’re seeking companies with innovative digital health solutions in the following clinical areas

a. Respiratory and Immunology - COPD, Severe Asthma, Lupus

b. Cardiovascular, Renal and Metabolic disease - Heart Failure, CKD

c. Oncology - Lung, Ovarian, Prostate, Breast, Hematologic or other cancer types

d. Vaccines and Infectious diseases – COVID, Flu

In addition, solutions should address at least one of the key challenges below: 

a. Early disease detection & disease management - Reduce the burden on healthcare systems by identifying patients for earlier diagnosis and empower the wider population with knowledge and tools to better understand and manage their disease

b. Multidisciplinary teams (MDT) support platforms & tools - Improve knowledge sharing and collaboration between physicians across specialties and healthcare organizations to drive better and faster treatment decisions for patients

c. Data insights, optimization & management - Facilitate data collection, sharing and analysis to generate meaningful scientific and medical insights supporting delivery of care in a compliant and efficient way 


Companies will be selected to the program based on the following criteria:

1. Maturity - the Company should have a product in the market, sufficient clinical evidence in place and regulatory approvals in at least one key market (or plan to gain such approvals within 6-8 months).

2. Scalability - the Company should be able to demonstrate the ability to scale globally beyond Israel and work with a high volume of users.

3. Stability - the Company should be currently funded, with a strong team and business model, and infrastructure in place.

4. Israel - the Company should be registered in Israel or have an active local presence.


Experts - Direct access to the industry leaders and partners’ networks, including global healthcare providers and payers, medical and regulatory experts and go to market specialists

Planning - Tailored and customized plan for a 9-month program to prepare for the next stage of scaling your digital health solution

Guidance - Receive consulting related to your value proposition, product/market fit and evaluation of clinical, technology, and business evidence

Validation - Strategic engagements with partners and potential customers to build and validate a viable use case

Deployment - Work directly with program partners to execute implementation pilots targeting scale

Networking and exposure - Enjoy links to the global network of the program partners including health systems, providers, payors, tech companies and others. Gain exposure to your targeted audience


August 2, 2022 – Application open

September 20, 2022 – Application close

November 14, 2022 – Selection committee decision and cohort onboarding

November 28, 2022 - Program begins

July 27, 2023 - Cohort graduation


As an owner of BeyondBio programs, AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.


In 2019, AstraZeneca launched BeyondBio, its investment program in research and innovation in Israel. BeyondBio is part of a global network of innovation hubs and runs several projects in Israel with multiple partners. AstraZeneca opened its Israeli office in 2008.

AstraZeneca Israel

Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Technology and Operations services and Accenture Song — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 699,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities.

Accenture life sciences helps the World’s leading biopharma companies bring their vision to life – enabling them to improve outcomes by converging around the patient, connecting scientific expertise with unique insights into the patient experience. Our services span across the entire life sciences enterprise, from research laboratories, clinical trials, and regulatory services, to pharmacovigilance and patient services solutions. Delivered by biopharma and biotech experts, our services are powered by an integrated, intelligent technology solution – the Accenture INTIENT platform.

Accenture Health harnesses the power of technology and human ingenuity to help clients improve access, experience, and outcomes in healthcare. With the help of our innovative, technology-enabled services, clients are delivering effective and personalized experiences that humanize healthcare for all.

Visit us at

Find out more on Accenture Life Sciences here:

For more information on Accenture Health visit at

AWS is the trusted technology partner to the global healthcare and life sciences industry. For over 14 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. Trusted by thousands of healthcare and life sciences customers around the world—including the fastest-growing startups, the largest enterprises, and the leading government agencies. AWS offers secure and compliant solutions to keep protected health information (PHI) private enabling the highly regulated healthcare and life sciences industry to increase the pace of innovation, unlock the potential of data, improve clinical and operational efficiency, and personalize the healthcare journey, improving the healthcare experience and ultimately patient outcomes.

Clalit, the largest and leading HMO in Israel, provides medical services to more than 52% of the Israeli population, with a wide range of medical services: outpatient clinics throughout the country, where there are women's health centers, pediatric health centers, and specialized medical centers. In addition, Clalit manages 14 public hospitals, and provides an additional set of services through subsidiary companies that include the network of dental clinics Clalit Smile, Clalit Aesthetics, Clalit Complementary Medicine, and 'Mor' Medical Institutes and Services. Clalit works to prevent disease and promote a healthy lifestyle through offering quality medical services, and advanced on-line services that provide the ability to receive medical services from anywhere, and at any time.


Early Cancer Detection Platform

Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, sophisticated signal processing and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. In a collaboration with AstraZeneca’s global R&D teams, C2i’s tumor burden monitoring technology was successfully validated and determined to be suitable for further collaboration which is currently being scoped.

Digital Pathology AI Tool

Ibex offers the most widely-deployed artificial intelligence platform in pathology, helping physicians streamline diagnostic workflows. The company signed and is currently operationalizing, a validation agreement with AstraZeneca for a digital pathology tool.

CKD prediction using EHR data

In collaboration with local and global AstraZeneca teams, Medial EarlySign used its purpose-built AI infrastructure to develop an algorithm predicting the risk of Chronic Kidney Disease (CKD) fast progression. The company is now in advanced discussions towards deployment of the solution in large healthcare systems in the US, in collaboration with AstraZeneca. Readiness for scale was advanced through a deployment architecture developed with Accenture.

Voice-based Heart Failure management

Using a patient’s speech, sampled via a mobile device, Cordio HearO™ senses fluid accumulation related to congestive heart failure and alerts healthcare providers and physicians to drive improved care. Cordio is working with AstraZeneca Spain to launch the company’s voice-based heart failure management solution in two leading European hospitals. In addition, a dialogue was initiated with an AWS speech-analysis team.

Asthma Digital Therapeutics Platform

Together with Astra Zeneca, has launched a clinical study in Israel and Switzerland that will use their platform to develop next-generation asthma management algorithms. docdok’s digital therapeutics platform drives value-based healthcare by capturing, understanding, and enhancing real-world patient outcomes using digital data.

Quathealth Logo

1 8

For medical inquiries about our products, please use the following email:

For other questions, please call 073-222-6099.

Lines are open from Sunday-Thursday, 8am-5pm (excluding holidays).

You can use this form to report adverse events or product quality complaint. You can also use the following email: